AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Citron, D. M.
Right arrow Articles by Appleman, M. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Citron, D. M.
Right arrow Articles by Appleman, M. D.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, January 2001, p. 345-348, Vol. 45, No. 1
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.1.345-348.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Comparative In Vitro Activities of ABT-773 against 362 Clinical Isolates of Anaerobic Bacteria

Diane M. Citron1,* and Maria D. Appleman1,2

Microbial Research Laboratory1 and Department of Pathology,2 Los Angeles County- University of Southern California Medical Center, Los Angeles, California

Received 7 March 2000/Returned for modification 29 July 2000/Accepted 17 October 2000

The activity of ABT-773, a novel ketolide antibiotic, against clinical isolates of anaerobic bacteria was determined and compared to the activities of other antimicrobial agents. MICs at which 90% of isolates were inhibited (MIC90s) were <= 0.06 µg/ml for Actinomyces spp., Clostridium perfringens, Peptostreptococcus spp., Propionibacterium spp., and Porphyromonas spp. The MIC50s and MIC90s were <= 0.06 and >32 µg/ml, respectively, for Eubacterium spp., Lactobacillus spp., Clostridium difficile, and Clostridium ramosum. The MIC90 for Bilophila wadsworthia, Bacteroides ureolyticus, and Campylobacter gracilis was 1 µg/ml, and that for Prevotella bivia and other Prevotella spp. was 0.5 µg/ml. The MIC90 for Fusobacterium nucleatum was 8 µg/ml, and that for Fusobacterium mortiferum and Fusobacterium varium was >32 µg/ml. The MIC90s for the Bacteroides fragilis group were as follows: for B. fragilis, 8 µg/ml; for Bacteroides thetaiotaomicron, Bacteroides ovatus, Bacteroides distasonis, and Bacteroides uniformis, >32 µg/ml; and for Bacteroides vulgatus, 4 µg/ml. Telithromycin MICs for the B. fragilis group were usually 1 to 2 dilutions higher than ABT-773 MICs. For all strains, ABT-773 was more active than erythromycin by 4 or more dilutions, and for some strains this drug was more active than clindamycin.

* Corresponding author. Mailing address: LAC+USC Medical Center, General Labs Bldg., Room 2G-24, 1801 East Marengo St., Los Angeles, CA 90033. Phone: (323) 226-3749. Fax: (323) 226-7021. E-mail: dcitron{at}hsc.usc.edu.

Antimicrobial Agents and Chemotherapy, January 2001, p. 345-348, Vol. 45, No. 1
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.1.345-348.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2001 by the American Society for Microbiology. All rights reserved.